GE Healthcare has submitted a new drug application to the FDA and a marketing authorization application to the European Medicines Agency for its PET imaging agent 18F-flutemetamol. Both applications seek approval for the use of the imaging agent in visualizing beta amyloid levels in the brains of adults being assessed for Alzheimer's disease.

Full Story:

Related Summaries